T. Rowe Price Associates’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17.3M | Sell |
2,567,478
-169,289
| -6% | -$1.14M | ﹤0.01% | 988 |
|
|
2025
Q1 | $24.7M | Sell |
2,736,767
-166,258
| -6% | -$1.5M | ﹤0.01% | 900 |
|
|
2024
Q4 | $50.2M | Sell |
2,903,025
-146,547
| -5% | -$2.53M | 0.01% | 750 |
|
|
2024
Q3 | $48.7M | Sell |
3,049,572
-84,886
| -3% | -$1.36M | 0.01% | 764 |
|
|
2024
Q2 | $44.7M | Buy |
3,134,458
+381,101
| +14% | +$5.43M | 0.01% | 757 |
|
|
2024
Q1 | $39M | Sell |
2,753,357
-256,316
| -9% | -$3.63M | ﹤0.01% | 786 |
|
|
2023
Q4 | $45.4M | Buy |
3,009,673
+9,636
| +0.3% | +$145K | 0.01% | 735 |
|
|
2023
Q3 | $47.4M | Buy |
3,000,037
+61,729
| +2% | +$975K | 0.01% | 695 |
|
|
2023
Q2 | $44.5M | Sell |
2,938,308
-45,555
| -2% | -$690K | 0.01% | 733 |
|
|
2023
Q1 | $43.3M | Sell |
2,983,863
-30,514
| -1% | -$442K | 0.01% | 716 |
|
|
2022
Q4 | $40.8M | Buy |
3,014,377
+42,327
| +1% | +$572K | 0.01% | 717 |
|
|
2022
Q3 | $46.8M | Buy |
2,972,050
+534,552
| +22% | +$8.42M | 0.01% | 667 |
|
|
2022
Q2 | $29.7M | Sell |
2,437,498
-57,216
| -2% | -$697K | ﹤0.01% | 1051 |
|
|
2022
Q1 | $23.4M | Buy |
2,494,714
+474,077
| +23% | +$4.45M | ﹤0.01% | 1192 |
|
|
2021
Q4 | $34.6M | Buy |
+2,020,637
| New | +$34.6M | ﹤0.01% | 1127 |
|